

September 8, 2016

The Honorable Fred Upton  
Chairman  
House Energy & Commerce Committee  
Washington, D.C. 20515

The Honorable Frank Pallone  
Ranking Member  
House Energy and Commerce Committee  
Washington, D.C. 20515

The Honorable Joe Pitts  
Chairman  
Health Subcommittee  
Washington, D.C. 20515

The Honorable Gene Green  
Ranking Member  
Health Subcommittee  
Washington, D.C. 20515

The Honorable Pete Olson  
U.S House of Representatives  
2133 Rayburn House Office Bldg.  
Washington, D.C. 20515

The Honorable Dave Loebsack  
U.S. House of Representatives  
1527 Longworth House Office Bldg.  
Washington, D.C. 20515

Dear Representatives Upton, Pallone, Pitts, Green, Olson and Loebsack,

The undersigned organizations, representing physicians, allied health professionals, patients, community health organizations and industry, commend you for holding a hearing on September 8th regarding H.R. 1192, "The National Diabetes Clinical Care Commission Act." We urge passage by the Energy and Commerce Committee as soon as possible to facilitate expedited approval by the House and subsequent approval by the Senate this year.

We are very hopeful that the Committee's action will allow for enactment of H.R. 1192 this year and help the nation pivot from continuing the status quo to instead undertaking more proactive and innovative approaches to metabolic, autoimmune and insulin resistant diseases, which include the escalating diabetes epidemic and the chronic disease complications of diabetes. The United States spends \$322 billion annually controlling the high blood glucose levels that characterize diabetes or the cardiac, nerve, kidney and newly recognized cancer-related complications of the disease. At this level of investment, the nation cannot afford to be complacent and accept inefficiencies and inconsistent policies as part of the federal response to a disease that continues to grow unchecked.

As you know, H.R. 1192 creates a commission which would include leaders of the federal government as well as several private sector experts in diabetes and its disease complications. The commission would review the myriad of ways the government currently spends money on activities related to the diagnosis and treatment of diabetes and other metabolic, autoimmune and insulin resistant diseases, and make recommendations on how these funds could be utilized more effectively.

Through innovation, collaboration, and application of advances in care called for in this important legislation, H.R. 1192 provides the opportunity to begin to reduce the staggering impact of diabetes on health care spending, while simultaneously improving care for the tens of millions of Americans living with diabetes, and the many more tens of millions of Americans impacted by diabetes.

We thank you and the Members of the Energy and Commerce Committee for taking action to advance H.R. 1192 and we are gratified by the support of the 220 co-sponsors of this bill. We look forward to working with you to secure its passage by the House of Representatives and the Senate this year.

Sincerely,

Abbott  
Academy of Nutrition and Dietetics  
American Academy of Family Physicians  
American Academy of Ophthalmology  
American Association of Clinical Endocrinologists  
American Association of Diabetes Educators  
American Association of Kidney Patients  
American Clinical Laboratory Association  
American College of Cardiology  
American Diabetes Association  
American Medical Association  
American Optometric Association  
American Pharmacists Association  
American Society for Metabolic and Bariatric Surgery  
American Society of Endocrine Physician Assistants  
American Society of Nephrology  
AstraZeneca  
Becton Dickinson and Company  
Board for Certification of Nutrition Specialists  
Children with Diabetes  
Dexcom, Inc.  
Diabetes Hands Foundation  
Diabetes Patient Advocacy Coalition  
diaTribe Foundation  
Eli Lilly and Company  
Endocrine Society  
Healthcare Leadership Council  
Health Monitor Network  
Johnson & Johnson  
JDRF  
Medtronic  
National Kidney Foundation  
Novo Nordisk, Inc.  
Obesity Action Coalition  
Obesity Medicine Association  
Omada Health, Inc.  
Renal Physicians Association  
Roche Diabetes Care, Inc.  
Sanofi  
The Obesity Society  
Vivus, Inc.  
Weight Watchers International  
YMCA of the USA